'No Ink on Tumor' Better in Breast Cancer

Share this content:
'No Ink on Tumor' Better in Breast Cancer
'No Ink on Tumor' Better in Breast Cancer

(HealthDay News) — Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with increased risk of ipsilateral breast tumor recurrence (IBTR), according to consensus guidelines published online Feb. 10 in the Journal of Clinical Oncology.

Meena S. Moran, MD, from the Yale University School of Medicine in New Haven, CT, and colleagues conducted a systematic review of 33 studies involving 28,162 patients. The researchers sought to reach a consensus regarding optimal margin width in breast-conserving surgery for invasive breast cancer and the risk of IBTR.

RELATED: Breast Cancer Resource Center

The researchers found that, compared with negative margins, positive margins (ink on invasive carcinoma or ductal carcinoma in situ) correlated with a two-fold increase in IBTR risk. Neither favorable biology, nor endocrine therapy, nor radiation boost mitigated the increased risk.

Compared with no ink on tumor, more widely clear margins did not significantly decrease the rate of IBTR. No evidence was observed in support of more widely clear margins for reducing IBTR in young patients or for patients with unfavorable biology, lobular cancers, or cancers with an extensive intraductal component.

"The use of no ink on tumor as the standard for an adequate margin in invasive cancer in the era of multidisciplinary therapy is associated with low rates of IBTR and has the potential to decrease re-excision rates, improve cosmetic outcomes, and decrease health care costs," the researchers wrote.

Several researchers disclosed financial ties to the medical device industry.

References

  1. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. J Clin Oncol. 2014;doi:10.1200/JCO.2013.53.3935.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs